ZYME — Zymeworks Inc.

Summary of Zymeworks Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $2.4 million for Q1 2026, a significant drop from $27.1 million in Q1 2025, primarily due to nonrecurring clinical milestones achieved in the previous year.
• Operating Expenses: $49.5 million, down from $52.7 million in the prior year, attributed to reduced third-party program costs and lower general and administrative expenses.
• Net Loss: $44.2 million, compared to a net loss of $22.6 million in Q1 2025, largely due to decreased revenue.
• Cash Position: $403.8 million as of March 31, 2026, up from $270.6 million at year-end 2025, providing a strong cash runway expected to fund operations beyond 2028.
• Share Repurchase Program: Approximately $95.8 million utilized to buy back 3.93 million shares at an average price of $24.37 per share.

2. Strategic Updates and Business Highlights

• Regulatory Milestones: PDUFA date for zanatumab in first-line GEA set for August 25, 2026, with significant milestone payments expected from partners Jazz and BeiGene.
• ADC Portfolio Development: Progress in the pan-RAS ADC platform, with promising preclinical data presented at AACR, including three new RAS-targeting ADC candidates.
• Leadership Changes: Strengthened leadership team with new appointments, including a General Counsel from Pfizer, aimed at enhancing strategic capital allocation and deal-making capabilities.

3. Forward Guidance and Outlook

• Anticipation of milestone payments totaling $440 million upon potential approvals of zanatumab in multiple regions.
• Continued focus on advancing clinical programs, particularly ZW191 and ZW251, with updates expected at upcoming medical meetings.
• Guidance for an IND filing for ZW1528 pushed to 2027, allowing for deeper understanding of IL-33 biology.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Significant year-over-year revenue decrease raises concerns about the sustainability of income streams.
• Increased Net Loss: The widening net loss may indicate challenges in managing expenses relative to revenue generation.
• Market Pressures: Jazz's comments on MFN pricing headwinds for Zahera could impact royalty revenues from international markets.
• Competitive Landscape: The oncology space remains highly competitive, particularly for ZW191, which may affect the speed and scale of development without partnerships.

5. Notable Q&A Insights

• Data Cadence: Management indicated a steady flow of updates expected throughout 2026, particularly from oncology meetings.
• Partnership Strategy: Ongoing discussions for partnerships to share capital and risk, especially for advancing ZW191 and other assets.
• Clinical Development Focus: ZW191 shows strong efficacy in challenging patient populations, with plans to optimize dosing and explore combination therapies.
• Pan-RAS ADC Development: The company is strategically positioning multiple ADCs across different tumor types, emphasizing flexibility and optionality in development paths.

Overall, Zymeworks is navigating a challenging financial landscape while making strategic advancements in its clinical pipeline and maintaining a robust cash position to support future growth.